Bodi Zhang
Research Subjects
Research Interests
Bodi Zhang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Akrivi Manola
Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, Boston, MA 02111, USA
1 shared publication - Brent A. Bauer
Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA
1 shared publication - Caleb M. Schmidt
Sovaris Aerospace, Boulder, CO 80302, USA
1 shared publication - Cem Meydan
Thorne Research, Inc., Summerville, SC 29483, USA
1 shared publication - Christopher E. Mason
Department of Physiology and Biophysics, Weill Cornell Medicine, New York, USA
1 shared publication - Duraisamy Kempuraj
Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, Boston, MA 02111, USA
1 shared publication
Latest Publications
- Open Access
- 20 July 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (7) , 396
A Multiomics, Molecular Atlas of Breast Cancer Survivors
Breast cancer imposes a significant burden globally. While the survival rate is steadily improving, much remains to be elucidated. This observational, single time point, multiomic study utilizing genomics, proteomics, targeted and untargeted metabolomics, and metagenomics in a breast cancer survivor (BCS) and age-matched healthy control cohort (N = 100) provides deep molecular phenotyping of breast cancer survivors. In this study, the BCS cohort had significantly higher polygenic risk scores for breast cancer than the control group. Carnitine and hexanoyl carnitine were significantly different. Several bile acid and fatty acid metabolites were significantly dissimilar, most notably the Omega-3 Index (O3I) (significantly lower in BCS). Proteomic and metagenomic analyses identified group and pathway differences, which warrant further investigation. The database built from this study contributes a wealth of data on breast cancer survivorship where there has been a paucity, affording the ability to identify patterns and novel insights that can drive new hypotheses and inform future research. Expansion of this database in the treatment-naïve, newly diagnosed, controlling for treatment confounders, and through the disease progression, can be leveraged to profile and contextualize breast cancer and breast cancer survivorship, potentially leading to the development of new strategies to combat this disease and improve the quality of life for its victims.
- 20 July 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (7) , 396
Open AccessA Multiomics, Molecular Atlas of Breast Cancer Survivors
Breast cancer imposes a significant burden globally. While the survival rate is steadily improving, much remains to be elucidated. This observational, single time point, multiomic study utilizing genomics, proteomics, targeted and untargeted metabolomics, and metagenomics in a breast cancer survivor (BCS) and age-matched healthy control cohort (N = 100) provides deep molecular phenotyping of breast cancer survivors. In this study, the BCS cohort had significantly higher polygenic risk scores for breast cancer than the control group. Carnitine and hexanoyl carnitine were significantly different. Several bile acid and fatty acid metabolites were significantly dissimilar, most notably the Omega-3 Index (O3I) (significantly lower in BCS). Proteomic and metagenomic analyses identified group and pathway differences, which warrant further investigation. The database built from this study contributes a wealth of data on breast cancer survivorship where there has been a paucity, affording the ability to identify patterns and novel insights that can drive new hypotheses and inform future research. Expansion of this database in the treatment-naïve, newly diagnosed, controlling for treatment confounders, and through the disease progression, can be leveraged to profile and contextualize breast cancer and breast cancer survivorship, potentially leading to the development of new strategies to combat this disease and improve the quality of life for its victims.
- Open Access
- 11 March 2010
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 7 (1) , 20
Mercury induces inflammatory mediator release from human mast cells
Background: Mercury is known to be neurotoxic, but its effects on the immune system are less well known. Mast cells are involved in allergic reactions, but also in innate and acquired immunity, as well as in inflammation. Many patients with Autism Spectrum Disorders (ASD) have "allergic" symptoms; moreover, the prevalence of ASD in patients with mastocytosis, characterized by numerous hyperactive mast cells in most tissues, is 10-fold higher than the general population suggesting mast cell involvement. We, therefore, investigated the effect of mercuric chloride (HgCl2) on human mast cell activation.Methods: Human leukemic cultured LAD2 mast cells and normal human umbilical cord blood-derived cultured mast cells (hCBMCs) were stimulated by HgCl2 (0.1-10 μM) for either 10 min for beta-hexosaminidase release or 24 hr for measuring vascular endothelial growth factor (VEGF) and IL-6 release by ELISA.Results: HgCl2induced a 2-fold increase in β-hexosaminidase release, and also significant VEGF release at 0.1 and 1 μM (311 ± 32 pg/106cells and 443 ± 143 pg/106cells, respectively) from LAD2 mast cells compared to control cells (227 ± 17 pg/106cells, n = 5, p < 0.05). Addition of HgCl2(0.1 μM) to the proinflammatory neuropeptide substance P (SP, 0.1 μM) had synergestic action in inducing VEGF from LAD2 mast cells. HgCl2also stimulated significant VEGF release (360 ± 100 pg/106cells at 1 μM, n = 5, p < 0.05) from hCBMCs compared to control cells (182 ± 57 pg/106cells), and IL-6 release (466 ± 57 pg/106cells at 0.1 μM) compared to untreated cells (13 ± 25 pg/106cells, n = 5, p < 0.05). Addition of HgCl2(0.1 μM) to SP (5 μM) further increased IL-6 release.Conclusions: HgCl2stimulates VEGF and IL-6 release from human mast cells. This phenomenon could disrupt the blood-brain-barrier and permit brain inflammation. As a result, the findings of the present study provide a biological mechanism for how low levels of mercury may contribute to ASD pathogenesis.
- 11 March 2010
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 7 (1) , 20
Open AccessMercury induces inflammatory mediator release from human mast cells
Background: Mercury is known to be neurotoxic, but its effects on the immune system are less well known. Mast cells are involved in allergic reactions, but also in innate and acquired immunity, as well as in inflammation. Many patients with Autism Spectrum Disorders (ASD) have "allergic" symptoms; moreover, the prevalence of ASD in patients with mastocytosis, characterized by numerous hyperactive mast cells in most tissues, is 10-fold higher than the general population suggesting mast cell involvement. We, therefore, investigated the effect of mercuric chloride (HgCl2) on human mast cell activation.Methods: Human leukemic cultured LAD2 mast cells and normal human umbilical cord blood-derived cultured mast cells (hCBMCs) were stimulated by HgCl2 (0.1-10 μM) for either 10 min for beta-hexosaminidase release or 24 hr for measuring vascular endothelial growth factor (VEGF) and IL-6 release by ELISA.Results: HgCl2induced a 2-fold increase in β-hexosaminidase release, and also significant VEGF release at 0.1 and 1 μM (311 ± 32 pg/106cells and 443 ± 143 pg/106cells, respectively) from LAD2 mast cells compared to control cells (227 ± 17 pg/106cells, n = 5, p < 0.05). Addition of HgCl2(0.1 μM) to the proinflammatory neuropeptide substance P (SP, 0.1 μM) had synergestic action in inducing VEGF from LAD2 mast cells. HgCl2also stimulated significant VEGF release (360 ± 100 pg/106cells at 1 μM, n = 5, p < 0.05) from hCBMCs compared to control cells (182 ± 57 pg/106cells), and IL-6 release (466 ± 57 pg/106cells at 0.1 μM) compared to untreated cells (13 ± 25 pg/106cells, n = 5, p < 0.05). Addition of HgCl2(0.1 μM) to SP (5 μM) further increased IL-6 release.Conclusions: HgCl2stimulates VEGF and IL-6 release from human mast cells. This phenomenon could disrupt the blood-brain-barrier and permit brain inflammation. As a result, the findings of the present study provide a biological mechanism for how low levels of mercury may contribute to ASD pathogenesis.